- Report
- March 2023
- 84 Pages
Middle East, Africa
From €1449EUR$1,500USD£1,239GBP
- Report
- March 2023
- 84 Pages
Asia Pacific
From €1449EUR$1,500USD£1,239GBP
- Report
- March 2023
- 85 Pages
Europe
From €1449EUR$1,500USD£1,239GBP
- Drug Pipelines
- June 2020
- 158 Pages
Global
From €3381EUR$3,500USD£2,891GBP
- Drug Pipelines
- December 2019
- 838 Pages
Global
From €2415EUR$2,500USD£2,065GBP
- Report
- April 2021
- 325 Pages
Global
From €2415EUR$2,500USD£2,065GBP
- Report
- May 2020
- 181 Pages
Global
From €3477EUR$3,600USD£2,974GBP
- Report
- May 2020
- 94 Pages
Middle East, Africa
From €1449EUR$1,500USD£1,239GBP
- Report
- May 2020
- 94 Pages
Asia Pacific
From €1449EUR$1,500USD£1,239GBP
- Report
- May 2020
- 94 Pages
Europe
From €1449EUR$1,500USD£1,239GBP
- Report
- May 2020
- 83 Pages
North America
From €1449EUR$1,500USD£1,239GBP
- Report
- February 2022
- 40 Pages
India
From €2507EUR$2,595USD£2,143GBP
- Report
- February 2022
- 40 Pages
Saudi Arabia
From €2507EUR$2,595USD£2,143GBP
- Report
- March 2020
- 100 Pages
Global
From €4632EUR$4,795USD£3,961GBP
- Report
- September 2019
- 100 Pages
Global
From €4632EUR$4,795USD£3,961GBP
- Report
- February 2024
- 83 Pages
Global
From €3500EUR$3,881USD£3,098GBP
- Report
- February 2024
- 96 Pages
Global
From €3500EUR$3,881USD£3,098GBP
- Report
- February 2024
- 101 Pages
Global
From €3500EUR$3,881USD£3,098GBP
- Report
- May 2023
- 146 Pages
Global
From €3500EUR$3,881USD£3,098GBP
- Report
- April 2023
- 84 Pages
Global
From €3500EUR$3,881USD£3,098GBP
Neuropathic pain is a type of chronic pain caused by damage to the nervous system. It is often described as a burning, tingling, or shooting sensation. Analgesics are medications used to reduce or eliminate pain. Neuropathic pain is often treated with a combination of analgesics, including non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and anticonvulsants. Other treatments may include physical therapy, nerve blocks, and electrical stimulation.
The neuropathic pain market is a rapidly growing segment of the analgesics market. It is driven by the increasing prevalence of chronic pain conditions, such as diabetes, cancer, and multiple sclerosis. The market is expected to benefit from the development of novel treatments, such as gene therapy and stem cell therapy.
Some companies in the neuropathic pain market include Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis, and Eli Lilly. Show Less Read more